|Study Description:||The goal of the first phase of this clinical research study is to learn the |
highest tolerable dose of plerixafor that can be given with G-CSF and the
standard of care chemotherapy drugs mitoxantrone, etoposide, and cytarabine
Plerixafor is designed to cause blood cells (blasts) to move out of the bone
marrow and into the blood stream where MEC may attack and kill the cancer cells.
MEC is commonly used in the treatment of AML. In this study, G-CSF is given to
help plerixafor to drive leukemic cells from the bone marrow.
Once the first phase of the study is completed, the second phase of the study
will determine whether the combination of plerixafor with G-CSF and MEC can be
more effective in treating leukemia than MEC alone.